GlassScriptPhysician profile
Jill Goldman
NPI 1083761480
$1,948.37
in general payments reported to CMS, 2019-2025
39 companies · $433 in 2025
The $433 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $107 · 2021: $150 · 2022: $264 · 2023: $263 · 2024: $732 · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,428.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $163.90 | 2023-2025 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $163.29 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $149.89 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $136.10 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $117.03 | 2021-2024 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $97.89 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $93.22 | 2021-2025 | Trintellix |
| Glaxosmithkline, LLC. | $92.14 | 2020 | |
| Idorsia Pharmaceuticals US INC | $85.08 | 2023-2024 | Tryvio, Quviviq |
| Amgen INC. | $82.52 | 2021-2025 | Prolia, Evenity, Repatha |
| Lundbeck LLC | $78.25 | 2023-2025 | Rexulti |
| Novo Nordisk INC | $73.33 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Biohaven Pharmaceutical Holding Company LTD. | $65.16 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $42.25 | 2025 | Ajovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.28 | 2021-2024 | Jardiance |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Goldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.